Scaling out these autologous cell therapies while considering individual patient processes is a new challenge.
|
This week's Fierce Drug Delivery is brought to you by GenScript.
Trouble viewing? Click here.
|
| | Free Whitepaper Download Hi E, check out this Fierce Biotech whitepaper we think you'll like: | |
|
|
| | | Many advancements are ongoing in science and technology, and advanced medicinal products are essential for the treatment and prevention of diseases. Gene and cell therapy, as well as immunotherapy products, belong to the advanced medicinal products category, and a wide variety of product platforms involve new technologies in development, production and control. Rapid expansion of the gene and cell therapy pipeline created constraints to accessing contract capacities around the globe. Innovation in gene and cell therapy expanded many drug development pipelines, and startups that are lacking internal production capacities heavily rely on contract manufacturing organization (CDMO).
Download this whitepaper to learn more. | |
|---|
| |
|
|
| | If you no longer wish to receive promotions from Fierce Life Sciences, simply unsubscribe.
Manage your newsletter subscriptions here.
Refer to our Privacy Policy.
Fierce LifeSciences is a division of Questex LLC.
685 3rd Ave 21st Floor New York, NY 10017
© 2020 Questex LLC. All Rights Reserved.
Reproduction in whole or in part is prohibited without written permission. | |
|
|
